Top priority
Oncology
- Breast cancer
- Colorectal cancer
- Lung cancer
- Pancreatic cancer
- Prostate cancer
- Ovarian cancer
For clinicians
Decision assistance. Not a replacement.
BioTwin gives clinicians novel longitudinal information about their patients' biology, behavior, and history to support earlier conversations and better-targeted decisions.
What BioTwin is, and what it is not
A virtual twin does not replace a clinician. A virtual twin is there to assist clinicians in making better-informed decisions. BioTwin is not and never will be an expert in oncology, neurology, or cardiology. BioTwin's role is to provide the data infrastructure that lets the experts do their best work, by giving them novel longitudinal information they do not otherwise have access to.
Where BioTwin is approved
- UAE Regulatory approved, breast and colorectal cancer screening decision assistance
- Canada Pending Health Canada review
- United States Pending FDA review
Health condition roadmap
BioTwin is building its clinical roadmap in stages, with oncology first, cardiology second, and neurology third.
Second priority
Cardiology
- Hypertension
- Heart failure
Third priority
Neurology
- Parkinson's disease
- Alzheimer's disease
- Epilepsy
- Major depressive disorder
The clinical role of the virtual twin
- Earlier and better-targeted screening conversations
- Longitudinal monitoring across repeated samples
- A discussion-ready summary for the clinician's decision-making